Company Overview and News

25
Rounds Report: The July 4th Weekend Procured Substantial Profits For Investors As Solid BioSciences Continued Its Rally

2018-07-12 seekingalpha
The overall bioscience market concluded the July 4th weekend with all sort of fireworks. Many equities under our coverage continued to procure further gains for investors.
CDTX SLDB PRTK FTSV MLNT IBB AKAO TTOO XBI

7
CDTX / Cidara Therapeutics, Inc. PROSPECTUS [RULE 424(B)(3)] (Prospectus)

2018-07-05 sec.gov
Document Filed Pursuant to Rule 424(b)(3) Registration File No. 333-225787
CDTX

7
Melinta Therapeutics: Could The H.R. 6294 Bill Improve The Prospects Of Antibiotic Innovators?

2018-07-05 seekingalpha
Despite that most companies in our various Specialty Reports have outperformed, the performance of the infectious disease innovators like Melinta are subpar to date.
CDTX PRTK MDCO MLNT TTOO

12
CDTX / Cidara Therapeutics, Inc. REGISTRATION STATEMENT

2018-06-21 sec.gov
Document As filed with the Securities and Exchange Commission on June 21, 2018 Registration Statement No. 333-
CDTX

10
CDTX / Cidara Therapeutics, Inc. FORM 8-K (Current Report)

2018-06-18 sec.gov
Document UNITED STATES
CDTX

145
Rounds Report: Ocular Rallied While Stellar FDA Due Diligence To Help Antibiotic Innovators

2018-06-13 seekingalpha
The overall bioscience market traded on an uptrend for the day. Many firms under our coverage continued to post further gains.
OCUL CDTX PRTK NVS IBB MLNT AKAO XBI RGEN

106
Integrated BioSci Research On Cidara Therapeutics: What's In Store For This Promising Antibiotic Innovator?

2018-06-08 seekingalpha
Wall Street has not been favoring infectious disease innovators. Nevertheless, the fundamentals of those firms are quite robust and are improving.
CDTX SGEN SESN PRTK MLNT AKAO

231
Rounds Report: Melinta Rallied While Novavax Experienced Significant Insider Purchases

2018-06-06 seekingalpha
The bioscience market traded slightly south with an overall skittish sentiment. Despite some key losers, many equities under our coverage continued to break the trend to post further gains.
CDTX MYL PRTK SPPI MDCO MLNT IBB AKAO XBI NVAX

14
CDTX / Cidara Therapeutics, Inc. WITHDRAWAL REQUEST

2018-06-05 sec.gov
Document Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101
CDTX

13
CDTX / Cidara Therapeutics, Inc. FORM S-3MEF

2018-06-05 sec.gov
Document As filed with the Securities and Exchange Commission on June 5, 2018
CDTX

7
CDTX / Cidara Therapeutics, Inc. / Biotechnology Value Fund L P - THE SCHEDULE 13G (Passive Investment)

2018-06-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G
CDTX

12
CDTX / Cidara Therapeutics, Inc. / Biotechnology Value Fund L P - THE SCHEDULE 13G (Passive Investment)

2018-06-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G
CDTX

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to CDTX / Cidara Therapeutics, Inc. on message board site Silicon Investor.

Colonial Data Tech (CDTX) Potential?
CUSIP: 171757107